May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Circulating Anti–Galectin–1 Antibodies Are Associated With the Severity of Ocular Disease in Autoimmune and Infectious Uveitis
Author Affiliations & Notes
  • C.P. Juarez
    Ophthalmology, Centro, Cordoba, Argentina
  • M.D. Romero
    Laboratory of Immunopathology, LIIDO, Cordoba, Argentina
  • J.C. Muiño
    Inmunology, Division Medicina III, Faculty of Medical Sciences, National University of Córdoba, Cordoba, Argentina
  • G.A. Bianco
    Immunogenetics, 1Division of Immunogenetics, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina
  • M. Ferrero
    Laboratory of Immunopathology, LIIDO, Cordoba, Argentina
  • G.A. Rabinovich
    Immunogenetics, 1Division of Immunogenetics, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina
  • J.D. Luna
    Ophthalmology, Fundación Ver, Cordoba, Argentina
  • Footnotes
    Commercial Relationships  C.P. Juarez, None; M.D. Romero, None; J.C. Muiño, None; G.A. Bianco, None; M. Ferrero, None; G.A. Rabinovich, None; J.D. Luna, None.
  • Footnotes
    Support  Agencia de Promoción Científica y Tecnológica (PICT 2003–05–13787), University of Buenos Aires (M091), Wellcome Trust, Fundación Sales, Fundación Antorchas and Mizutani Foundation for Glycoscience to
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3513. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.P. Juarez, M.D. Romero, J.C. Muiño, G.A. Bianco, M. Ferrero, G.A. Rabinovich, J.D. Luna; Circulating Anti–Galectin–1 Antibodies Are Associated With the Severity of Ocular Disease in Autoimmune and Infectious Uveitis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3513.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Recent evidence indicates that galectin–1 (Gal–1), an endogenous lectin found at sites of immune privilege, plays critical roles on immunoregulation. Therapeutic administration of Gal–1 or its genetic delivery suppresses inflammation in experimental models of autoimmunity including arthritis and uveitis. However, the impact of Gal–1 in chronic inflammation has not yet been explored in clinical settings. To investigate the occurrence of circulating anti–Gal–1 antibodies in patients with autoimmune and infectious uveitis as potential determinant factors of disease progression.

Methods: : IgG, IgE and IgA anti–Gal–1 antibodies were assessed by ELISA and Western blot in sera from patients with autoimmune (n=47) and infectious (n=15) uveitis compared to healthy controls (n=30). The frequency of anti–Gal–1 antibodies was examined in patients experiencing progressive or benign evolution. The ability of anti–Gal–1 antibodies to recognize retinal tissue was assessed by ELISA, Western blot and immunohistochemistry following elution of specific antibodies from nitrocellulose filters previously adsorbed with recombinant Gal–1 and further incubated with patient sera.

Results: : IgE, IgG and IgA anti–Gal–1 antibodies were increased in sera from patients with autoimmune uveitis (p<0.001 vs controls), and in toxoplasmic retinochoroiditis (p< 0.001). The frequency of anti–Gal–1 IgE and IgG antibodies was associated with progressive disease and poor outcome in autoimmune and infectious uveitis. Furthermore, anti–Gal–1 antibodies strongly immunoreacted with retinal cell lysates and recognized several retinal structures mainly photoreceptors and pigment epithelium in retinal sections.

Conclusions: : Anti–retinal Gal–1 antibodies are associated with the progression of ocular disease, suggesting their potential use for the follow–up of patients with uveitis.

Keywords: uveitis-clinical/animal model • uvea • autoimmune disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×